- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT00993499
Trial of Continuous Once Daily Oral Treatment Using BIBW 2992 (Afatinib) Plus Sirolimus (Rapamune®) in Patients With Non-small Cell Lung Cancer Harbouring an EGFR Mutation and/or Disease Progression Following Prior Erlotinib or Gefitinib
A Phase Ib Open Label Clinical Trial of Continuous Once Daily Oral Treatment Using BIBW 2992 Plus Sirolimus in Patients With Non-small Cell Lung Cancer Harbouring an EGFR Mutation and/or Disease Progression Following Prior Erlotinib or Gefitinib
The primary objective of this trial is to identify the Maximum Tolerated Dose of BIBW 2992 therapy when given continuously in combination with Sirolimus.
The MTD will be based on the Dose Limiting Toxicity information collected during the first two cycles.
Overall safety, pharmacokinetics and anti-tumour efficacy will be evaluated as secondary objectives.
Visão geral do estudo
Status
Intervenção / Tratamento
Tipo de estudo
Inscrição (Real)
Estágio
- Fase 1
Contactos e Locais
Locais de estudo
-
-
-
Badalona (Barcelona), Espanha
- 1200.70.34001 Boehringer Ingelheim Investigational Site
-
Barcelona, Espanha
- 1200.70.34008 Boehringer Ingelheim Investigational Site
-
Barcelona, Espanha
- 1200.70.34009 Boehringer Ingelheim Investigational Site
-
Girona, Espanha
- 1200.70.34006 Boehringer Ingelheim Investigational Site
-
L'Hospitalet de Llobregat (Barcelona), Espanha
- 1200.70.34007 Boehringer Ingelheim Investigational Site
-
Majadahonda (Madrid), Espanha
- 1200.70.34005 Boehringer Ingelheim Investigational Site
-
Valencia, Espanha
- 1200.70.34004 Boehringer Ingelheim Investigational Site
-
Zaragoza, Espanha
- 1200.70.34002 Boehringer Ingelheim Investigational Site
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion criteria:
- Pathologically or cytologically confirmed diagnosis of Stage IIIB or Stage IV NSCLC
- Patients who have failed conventional treatment (at least 1 prior treatment line), or for whom no therapy of proven efficacy exists
Patients whose tumors:
- are EGFR mutation-positive or
- are EGFR mutation-negative or unknown provided they had disease progression after achieving either response or stable disease for at least 6 months from a previous treatment with erlotinib (Tarceva®) or gefitinib (Iressa®)
- Patients aged 18 years or older
- Life expectancy of at least three (3) months
- Eastern Cooperative Oncology Group (ECOG, R01-0787) performance score 0-2
- Written informed consent that is consistent with ICH-GCP guidelines
Exclusion criteria:
- Prior major surgery, chemotherapy or radiation therapy within 4 weeks before start of therapy.
- Prior treatment with an mTOR inhibitor within the past 4 weeks before start of therapy or concomitantly with this study
- Use of erlotinib (Tarceva®) or gefitinib (Iressa®) within 14 days of run-in treatment with Sirolimus
- Active CNS metastases (defined as stable for <4 weeks and/or symptomatic and/or requiring treatment with anticonvulsants or steroids)
- Severe alteration in serum fasting cholesterol (equal or more than 350 mg/dL) or triglycerides (equal or more than 400 mg/dL). Patients may be allowed to enrol on the trial after initiation of lipid lowering agents.
Requirement for treatment with any of the prohibited concomitant medications:
- Concomitant CYP3A4 inhibitors within the past 7 days before start of therapy or concomitantly with this study.
- Concomitant CYP3A4 inducers within the past 14 days before start of therapy or concomitantly with this study.
- Any contraindications for therapy with Sirolimus.
- Known hypersensitivity to BIBW 2992, Sirolimus or other rapamycin analogues (everolimus, temsirolimus, deforolimus, etc.) or the excipients of any of the trial drugs.
- Use of any investigational drug within 4 weeks before start of therapy.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
---|---|
Experimental: BIBW 2992 + Sirolimus
Dose escalation of the combination BIBW 2992 plus Sirolimus.
|
Dose escalation (19-40 patients): low or high dose oral + 12 addit.
pat. at MTD, until progression or undue AEs
Dose escalation (19-40 patients): several dose levels + 12 addit.
pat. at MTD until progression or undue AEs.
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Occurrence of Dose Limiting Toxicities (DLT)
Prazo: 2 first cycles, 56 days
|
Number of participants with of dose limiting toxicities (DLT)
|
2 first cycles, 56 days
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Best Overall Response
Prazo: From first trial medication intake in the first treatment course until last trial medication intake plus 28 days, up to 367 days
|
Best overall response (unconfirmed) according to RECIST v1.1
|
From first trial medication intake in the first treatment course until last trial medication intake plus 28 days, up to 367 days
|
Objective Response
Prazo: From first trial medication intake in the first treatment course until last trial medication intake plus 28 days, up to 367 days
|
Rate of (unconfirmed) objective response, defined as complete response (CR) or partial response (PR) according to RECIST v1.1
|
From first trial medication intake in the first treatment course until last trial medication intake plus 28 days, up to 367 days
|
Rate of Disease Control
Prazo: From first trial medication intake in the first treatment course until last trial medication intake plus 28 days, up to 367 days
|
Rate of (unconfirmed) disease control defined as CR, PR, or stable disease (SD), according to RECIST v1.1
|
From first trial medication intake in the first treatment course until last trial medication intake plus 28 days, up to 367 days
|
Exploratory Examination of EGFR Mutations (Exons 19, 20 and 21 and Others) in Serum/Plasma DNA and Tumour DNA.
Prazo: Multiple time points during the trial
|
Exploratory examination of Epidermal growth factor (receptor)(EGFR) mutations (Exons 19, 20 and 21 and others) in serum/plasma DNA and tumour DNA. This endpoint was not analysed in the study report as the available data was too limited. |
Multiple time points during the trial
|
Maximum Measured Plasma Concentration of Afatinib at Steady State (Cmax,ss)
Prazo: 24 hours (h), 311h 55minutes (min), 312h, 313h, 314h, 315h, 316h, 317h, 318h, 320h and 336h after first administration of afatinib
|
Maximum measured plasma concentration of Afatinib at steady state (Cmax,ss)
|
24 hours (h), 311h 55minutes (min), 312h, 313h, 314h, 315h, 316h, 317h, 318h, 320h and 336h after first administration of afatinib
|
AUC of Afatinib at Steady State Over the Dosing Interval τ (AUCτ,ss)
Prazo: 24 hours (h), 311h 55minutes (min), 312h, 313h, 314h, 315h, 316h, 317h, 318h, 320h and 336h after first administration of afatinib
|
Area under the curve (AUC) of Afatinib at steady state over the dosing interval τ (AUCτ,ss) for afatinib.
|
24 hours (h), 311h 55minutes (min), 312h, 313h, 314h, 315h, 316h, 317h, 318h, 320h and 336h after first administration of afatinib
|
Maximum Measured Plasma Concentration of Sirolimus at Steady State (Cmax,ss)
Prazo: 24 hours (h) 5 minutes (min), 24h, 23h, 22h, 20h, 18h, 16h, 5min before first afatinib administration and 144h, 311h 55min, 312h, 313h, 314h, 315h, 316h, 317h, 318h, 320h, 336h, 480h after first administration of afatinib
|
Maximum measured plasma concentration of sirolimus at steady state (Cmax,ss)
|
24 hours (h) 5 minutes (min), 24h, 23h, 22h, 20h, 18h, 16h, 5min before first afatinib administration and 144h, 311h 55min, 312h, 313h, 314h, 315h, 316h, 317h, 318h, 320h, 336h, 480h after first administration of afatinib
|
AUC of Sirolimus at Steady State Over the Dosing Interval τ (AUCτ,ss)
Prazo: 24 hours (h) 5 minutes (min), 24h, 23h, 22h, 20h, 18h, 16h, 5min before first afatinib administration and 144h, 311h 55min, 312h, 313h, 314h, 315h, 316h, 317h, 318h, 320h, 336h, 480h after first administration of afatinib
|
Area under the curve (AUC) of sirolimus at steady state over the dosing interval τ (AUCτ,ss) for afatinib.
|
24 hours (h) 5 minutes (min), 24h, 23h, 22h, 20h, 18h, 16h, 5min before first afatinib administration and 144h, 311h 55min, 312h, 313h, 314h, 315h, 316h, 317h, 318h, 320h, 336h, 480h after first administration of afatinib
|
Occurrence of Adverse Events According to CTCAE, Version 3.0
Prazo: From first trial medication intake in the first treatment course until last trial medication intake plus 28 days, up to 367 days
|
Percentage of participants with adverse events according to highest Common Terminology Criteria for Adverse Events (CTCAE) grade, version 3.0
|
From first trial medication intake in the first treatment course until last trial medication intake plus 28 days, up to 367 days
|
Percentage of Patients With Drug-related AEs
Prazo: From first trial medication intake in the first treatment course until last trial medication intake plus 28 days, up to 367 days
|
Percentage of patients with drug-related adverse events (AEs).
|
From first trial medication intake in the first treatment course until last trial medication intake plus 28 days, up to 367 days
|
Frequency of Patients With Possible Clinically-significant Abnormalities in Liver Enzymes or Total Bilirubin
Prazo: From first trial medication intake in the first treatment course until last trial medication intake plus 28 days, up to 367 days
|
Evaluation of laboratory parameters included assessment of the frequency of patients with ALT and AST elevations concurrent with elevated bilirubin and indicative of Hy's law cases.
|
From first trial medication intake in the first treatment course until last trial medication intake plus 28 days, up to 367 days
|
Colaboradores e Investigadores
Patrocinador
Publicações e links úteis
Links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Atualizações de registro de estudo
Última Atualização Postada (Estimativa)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
- Processos Patológicos
- Doenças Respiratórias
- Neoplasias
- Doenças pulmonares
- Neoplasias por local
- Atributos da doença
- Neoplasias do Trato Respiratório
- Neoplasias Torácicas
- Carcinoma Broncogênico
- Neoplasias Brônquicas
- Neoplasias Pulmonares
- Progressão da doença
- Carcinoma pulmonar de células não pequenas
- Efeitos Fisiológicos das Drogas
- Mecanismos Moleculares de Ação Farmacológica
- Agentes Anti-Infecciosos
- Inibidores Enzimáticos
- Agentes Antineoplásicos
- Agentes imunossupressores
- Fatores imunológicos
- Agentes antibacterianos
- Inibidores de proteína quinase
- Antibióticos, Antineoplásicos
- Antifúngicos
- Sirolimo
- Afatinibe
Outros números de identificação do estudo
- 1200.70
- 2009-010432-18 (Número EudraCT: EudraCT)
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em BIBW 2992
-
Boehringer IngelheimConcluído
-
Boehringer IngelheimConcluídoGliomaEstados Unidos, Canadá
-
Centre Leon BerardBoehringer IngelheimConcluídoCarcinoma Espinocelular de Cabeça e PescoçoFrança
-
Boehringer IngelheimConcluídoNeoplasias da MamaEstados Unidos, Reino Unido
-
Boehringer IngelheimConcluído
-
Boehringer IngelheimConcluído
-
University of GuadalajaraConcluídoSíndrome metabólica
-
Boehringer IngelheimAprovado para comercializaçãoCarcinoma pulmonar de células não pequenasAustrália
-
Boehringer IngelheimConcluído
-
M.D. Anderson Cancer CenterBoehringer IngelheimRescindidoCâncer de pulmãoEstados Unidos